AzTrials
AzTrials

Colorectal DisordersCLEANNCT04225793

The Use of Osmotic Laxatives Versus Macrogol for Bowel Preparation in Patients Undergoing Colonoscopy

A study testing Eziklen® and MoviPrep in people with Colorectal Disorders, run by Russian Society of Colorectal Surgeons at 1 site in Russia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The gold standard of colorectal examination is colonoscopy. One of the main purposes of colonoscopy is detecting bowel neoplasms. Right now there are several methods the bowel preparation for the colonoscopy. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Colorectal Disorders
What is being tested?
Eziklen® and MoviPrep
Could I receive a placebo?
No, everyone receives an active treatment
How many people
98 participants
Where
1 siteRussia
Study dates
2 Jun 2019to 2 Aug 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed informed consent forms confirming the understanding of the course of study and agreement to participate in it.
  • A written patient consent to fill the prepared questionnaire and to perform diagnostic colonoscopy in case of following situations:
  • Routine oncological screening
  • Polyps or neoplasms in anamnesis
  • Anemia or latent bleeding diagnostics
  • Diarrhea or constipation with unknown reason
Show all 36Show fewer
  • Inflammatory bowel disease in remission
  • Pathological formation according to US examination (neoplasm evidence in abdomen)
  • Suspicious colon neoplasms according to CT and/or irrigography
  • ASA scale for physical status assessment ≤ 3
  • Patients with adequate electrolyte balance rate (K, Na, Cl, bicarbonate rate screening).
  • Non-inclusion criteria:
  • The baseline data about comorbidities or laboratory data that can jeopardize the safety of the patient or reduce the likelihood of obtaining satisfactory data necessary to achieve the goal (goals) of the study.
  • The presence of progressive carcinoma or other bowel disease, leading to excessive mucous membrane fragility.
  • The confirmed or suspected gastrointestinal (FA) obstruction, stagnation in the stomach, gastroparesis, or a violation of gastric evacuation.
  • The intestinal perforation.
  • The profuse vomiting.
  • The procedure goal to perform a medical procedure (eg, polypectomy, mucosectomy).
  • The presence of toxic colitis or megacolon.
  • Severe acute phase of inflammatory bowel disease as a contraindication to colonoscopy.
  • The presence of acute GI bleeding.
  • History of gastrointestinal surgery (for example, colostomy, colectomy, gastric bypass surgery, stomach resection).
  • The history of impaired consciousness predisposing to pulmonary aspiration.
  • The colonoscopy aimed remove a foreign body or decompression.
  • History of incomplete colonoscopy
  • The confirmed severe renal failure (glomerular filtration rate (GFR) <30 ml / min / 1.73 m2).
  • The confirmed severe liver failure (10-15 points on the Child-Pugh scale).
  • Dehydration condition requiring treatment.
  • The ascites.
  • Severe congestive heart failure (class III and IV).
  • The state of hyperuricemia with a clinic of gouty arthritis.
  • Pregnancy or lactation.
  • Patients at risk of pregnancy and not using an acceptable method of contraception during the study. Women of childbearing age must provide a negative pregnancy test at the beginning of the study and must use the oral contraceptive method, double (use a condom with spermicidal gel, birth control suppositories or films; diaphragm with spermicides; or male condom and diaphragm with spermicides), injection contraception or intrauterine devices . Non-fertile women - more than a year after menopause, after surgical sterilization or hysterectomy at least 3 months before the start of the study.
  • The hypersensitivity reaction to active substances or to other auxiliary substances (Eziklen and Moviprep).
  • A patient with a mental state that does not allow him to understand the nature, extent and possible consequences of the study and / or evidence of refusal to cooperate.
  • During the course of the study, the patient is likely to require treatment with drugs that are not permitted by the study protocol.

Who cannot join

  • The pregnancy
  • The inability to follow the protocol
  • Refuse of study participation.

Trial locations and contacts

1 site in 1 country.

Tatiana Garmanova, MD contact

+79773429249

tatianagarmanova@gmail.com

Daniil Markarian, MD contact

Russia1 site, 1 recruiting
  • Clinic of Colorectal and Minimally invasive surgery

    Moscow, 119435

    Inna Tulina, MD, +79264086672, tulina@kkmx.ru

    Petr Tsarkov, PhD

    Recruiting

Other trials in Russia

About this study

Official title: Comparative Analysis of the Osmotic Laxative Application Efficiency and Safety Eziclen and Moviprep for Colonoscopy Preparation

The gold standard of colorectal examination is colonoscopy. One of the main purposes of colonoscopy is detecting bowel neoplasms. Right now there are several methods the bowel preparation for the colonoscopy.

Several factors can affect the quality of the bowel preparation, such as the kind of oral laxative, the time after its intake and the diet followed in the days before colonoscopy. In this randomized clinical trial the investigators aimed to compare the safety and efficiency of two low-volume laxatives for bowel preparation: potassium, magnesium and sodium sulphates-based laxative Eziclen (IPSEN, France) and Macrogol-3350 + Sodium Sulfate + Potassium Chloride+ Sodium Chloride + Ascorbic Acid-based and Sodium Ascorbate-based Moviprep (Nordgine B.V., The Netherlands)

Read the detailed description

The key method of colorectal examination is colonoscopy. The result, diagnostic significance and therapeutic safety depend a lot on the quality of bowel preparation. One of the main purposes of colonoscopy is detecting the earliest forms of colorectal cancer and prognostically meaningful small nonpolyposis neoplasms. The good and perfect bowel preparation is essential in this case.

However, the bowel preparation for colonoscopy must fulfill the following criterias:

  • Be effective, that means to empty colon of faeces, residual liquid and foamy content fully and safely;
  • Harmless, no side effects on the other organs and systems;
  • Do not cause discomfort nor change to electrolyte balance, well tolerated;
  • Do not affect the severity of bowel disease nor cause macro- and microscopic colon mucose changes;
  • Quick response with short preparation period (no more than 24 hours);
  • Easy to use, so patient could perform it independently or with the least medical staff participation;
  • Do not require special conditions, equipment and staff training (possibility to perform at home);
  • Do not distort the endoscopic image (colour, shape, reflexion);
  • Do not limit the use of vital dyes or other means of endoscopic diagnosis and treatment;
  • Do not damage the endoscopic equipment;
  • be cheap . Bowel preparation schemes usually include diet (low-residue) and oral laxative intake. The low-residue diet should last no more than 24 hours before the colonoscopy according to the European Society of Gastrointestinal Endoscopy clinical recommendations.

The time factor is essential for quality of bowel preparation. If the colonoscopy is performed in the first half of day the intake of the part of laxatives (usually a half) on that day (split-mode or separate) provides a better result in comparison to full dose intake on the colonoscopy day or the evening before it.

Bowel preparation might be fully undertaken (in full volume) in the morning of examination day for patients undergoing colonoscopy in the afternoon according to some studies. In the case of laxative intake on the morning of examination day, excellent preparation quality and good patient tolerance was demonstrated in the Varughese S et al. research assessing 4 liters bowel preparation scheme efficiency for patients undergoing colonoscopy in the afternoon in comparison to intake in the evening before colonoscopy.

The patient's somatic status and the urgency should be considered for choosing the bowel preparation mode.

Polyethyleneglycol-based drugs have become more commonly used in clinical practice for colonoscopy bowel preparation since its appearance in 1980.

The drug passes through the intestine without being absorbed and metabolized and increases the bowel liquid volume, as do all osmotic laxatives. Thus, electrolyte balance is not disrupted and effective intestinal lavage occurs. But patient compliance might be influenced significantly due to a large volume intake requirement (4 l) and specific organoleptic feature.

Over the course of several years, European and Canadian experts have accepted the sodium picosulfate+ magnesium citrate-based low-volume bowel preparation method (2l) as alternative option and the FDA has also approved it in July 2012.

This combined intake scheme allows to prepare intestine efficiently for the examination. The sodium picosulfate has a bowel stimulating effect and as osmotic laxative magnesium citrate retains water. But the electrolyte balance changes and dehydration may also influence the patient compliance to laxative.

According to the international clinical recommendations for colonoscopy, 4l polyethylenуglycol-based laxative in split-mode preparation with an time interval no more than 4 hours from the end of preparation until colonoscopy is recommended as a standard method. Low-dose polyethylenуglycol-based laxative intake (2l) combined with ascorbate or sodium thiosulfate+ magnesium citrate can serve as alternative examination preparation method (especially for outpatients). Only polyethylenуglycol-based laxative can be recommended for patients with renal failure as bowel preparation method.

Eziclen - potassium, magnesium and sodium sulphates-based osmotic laxative for colonoscopy preparation registered in Russia doesn't have a strong evidence base and is not included in national recommendations yet due to its recent market entry (2018) But according to the registered multicenter controlled clinical trials assessing the potassium, magnesium and sodium sulfates vs. 2l polyethyleneglycol with electrolytes efficiency for colonoscopy preparation in split-mode (n=356) and one-day preparation (n=364) (primary endpoint - bowel purity degree as "perfect", "good", "bad") as well as non-conceded Eziclen efficiency was identified in comparing to the control group (97,2% vs 96,1% and 84% vs 82,9% respectively). The side effects frequency was also comparable with control group. There was shown a comparable rate of effective bowel preparation (97,2% vs 97,7%) on a background of higher patient compliance (95,7 % comparing to 82,3 %) in a similar study assessing Eziclen efficiency, safety and patient compliancy in comparison with Macrogol 400 with electrolytes.

So the investigators aimed our study to investigate efficiency, safety and compliance of two low-volume laxatives Potassium Sulfate+ Magnesium Sulfate+ Sodium Sulfate-based (Eziclen) vs. relevant volume of Macrogol-3350+ Sodium Sulfate+ Potassium Chloride+ Sodium Chloride+ Ascorbic Acid and Sodium Ascorbate-based (Moviprep) in bowel preparation for colonoscopy.

Being tested
Eziklen®, MoviPrep
Keywords
colorectal cancer, colonoscopy, Eziclen
Medical subject headings
Colorectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Eziklen®Drug

    Also called esiclene, Eziklen

    The Eziclen solution should be taken in the one-time use regimen in morning before procedure.

    Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure.

  • MoviPrepDrug

    Also called Moviprep, macrogol

    The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.

    Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure.

Study groups in NCT04225793
Study groupRoleWhat they receive
Eziklen®Active comparatorpotassium, magnesium and sodium sulphates-based laxative
Receives: Drug: Eziklen®
MacrogolActive comparatorMacrogol-3350 + Sodium Sulfate + Potassium Chloride+ Sodium Chloride + Ascorbic Acid-based and Sodium Ascorbate-based Moviprep
Receives: Drug: MoviPrep

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of bowel preparation according to Boston Bowel Preparation Scale

    Total score of bowel preparation measured from 0 to 9. The maximum BBPS score for a perfectly clean colon without any residual liquid is 9 and the minimum BBPS score for an unprepared colon is 0. This is evaluated by the endoscopist

    Measured: during the procedure

Secondary outcomes (8)
  1. Patient compliance to preparation

    is measured with a specially designed questionnaire, 4 points, where 0 is very use it again and 4 will advise to all

    Measured: 1 houre before procedure

  2. adverse events rate

    is measured as from 0 to 4 in case of presence any complication (nausea or vomiting or headache or abdominal pain related to preparation)

    Measured: starting 1 day before the procedure and within 2 weeks after

  3. The polyps detection rate

    is measured as 0 in cases there were no polyps or 1 in case if there were polyps detected by colonoscopy

    Measured: during the procedure

  4. Researcher satisfaction with preparation

    Satisfaction of the operator will be evaluated on a 5-point Likert scale with a range from 0 to 4 points, where 0 is insufficient and 4 complete bowel preparation.

    Measured: during the procedure

  5. sodium blood level

    mg per ml

    Measured: one the day before procedure and one houre before procedure

  6. potassium blood level

    tmg per ml

    Measured: one the day before procedure and one houre before procedure

  7. creatinine blood level

    mg per dl

    Measured: one the day before procedure and one houre before procedure

  8. urea blood serum level

    mg per ml

    Measured: one the day before procedure and one houre before procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2020
  2. Study start2 Jun 2019
  3. Primary completion2 Jun 2020 (estimated)
  4. Study completion2 Aug 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
98 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04225793
Sponsor's protocol ID
685476
Acronym
CLEAN
Status last verified
May 2020
First submitted
24 Oct 2019
Last updated
19 May 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Eziklen® and MoviPrep in people with Colorectal Disorders, run by Russian Society of Colorectal Surgeons at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 36 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tatiana Garmanova, MD (+79773429249, tatianagarmanova@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of bowel preparation according to Boston Bowel Preparation Scale (time frame: during the procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in